Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Director | June 08, 2023 | June 12, 2023 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 10, 2026 | June 12, 2026 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Director | June 26, 2019 | June 27, 2019 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | May 24, 2006 | May 25, 2006 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-06-08 | Direct | 6,500 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The shares subject to the options shall vest 25% every quarter after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the options shall vest 25% every quarter after the grant date.
LIGAND PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,969 |
Ending reported balance
After 2026-06-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-10 · Sale · Disposed 257 · Balance 31,303 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-06-10 · Sale · Disposed 232 · Balance 31,071 F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-06-10 · Sale · Disposed 697 · Balance 30,374 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-06-10 · Sale · Disposed 3,405 · Balance 26,969 F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Larimar Therapeutics, Inc.
Report date June 26, 2019 · Filed June 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2029-06-26 | Direct | 27,000 |
Reported balance
After 2019-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-26 · Grant · Acquired 27,000 · Balance 27,000 F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.
THERMO FISHER SCIENTIFIC INC.
Report date May 24, 2006 · Filed May 25, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2013-05-24 | Direct | 10,500 |
Reported balance
After 2006-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-05-24 · Grant · Acquired 10,500 · Balance 10,500 F1: The option vests in three equal annual installments beginning on May 24, 2007. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning on May 24, 2007.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PFIZER INC
Report date October 15, 2007 · Filed October 17, 2007
Section 16 reporting ended · disclosed 2007-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 57,875 |
Reported balance
After 2007-10-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2007-10-15 · Grant · Acquired 214 · Balance 57,875 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 21:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,405 | $251.62 | $856,751.80 |
DisclosureSEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 4 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,969 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 697 | $249.53 | $173,924.22 |
DisclosureSEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,374 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 232 | $248.11 | $57,561.78 |
DisclosureSEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,071 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 257 | $247.22 | $63,536.49 |
DisclosureSEC source: 0002001011-26-000102 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,303 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,938 | $0.00 Strike: $237.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000099 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 836 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000099 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,560 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| March 06, 2026 Filed Mar 31, 2026 21:53 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,161 | $0.00 Strike: $114.15 | $0.00 |
DisclosureSEC source: 0002001011-26-000036 · primary_doc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,161 shares Expires 2028-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,474 shares, which vested in full on June 6, 2019, at an exercise price of $195.91 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| March 06, 2026 Filed Mar 31, 2026 21:53 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,161 | $200.76 | $433,842.36 |
DisclosureSEC source: 0002001011-26-000036 · primary_doc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,724 Read SEC document |
| March 06, 2026 Filed Mar 31, 2026 21:53 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,161 | $114.15 | $246,678.15 |
DisclosureSEC source: 0002001011-26-000036 · primary_doc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,034 | $0.00 Strike: $69.51 | $0.00 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · derivative · entry 6 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,034 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,145 | $0.00 Strike: $66.13 | $0.00 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · derivative · entry 5 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,145 shares Expires 2027-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,456 shares, which vested in full on May 25, 2018, at an exercise price of $113.5000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,034 | $205.45 | $417,885.30 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 4 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,724 Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,034 | $69.51 | $141,383.34 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,145 | $205.45 | $440,690.25 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,724 Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,145 | $66.13 | $141,848.85 |
DisclosureSEC source: 0002001011-25-000097 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,783 | $0.00 Strike: $105.99 | $0.00 |
DisclosureSEC source: 0002001011-25-000044 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,209 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000044 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,724 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,406 | $0.00 Strike: $52.30 | $0.00 |
DisclosureSEC source: 0002001011-24-000093 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,406 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 2,754 shares on April 24, 2015, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,406 | $123.65 | $297,501.90 |
DisclosureSEC source: 0002001011-24-000093 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,515 Read SEC document |
| November 27, 2024 Filed Dec 3, 2024 01:05 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,406 | $52.30 | $125,833.80 |
DisclosureSEC source: 0002001011-24-000093 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0002001011-24-000059 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000059 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,515 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,461 | $0.00 Strike: $73.76 | $0.00 |
DisclosureSEC source: 0000886163-23-000042 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 Underlying: Common Stock · 5,461 shares Expires 2033-06-09 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-23-000042 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,263 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:54 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070402 · tm2318426-6_4seq1.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| January 15, 2023 Filed Jan 17, 2023 11:29 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 15,125 | $4.00 | $60,500.00 |
DisclosureSEC source: 0001104659-23-004007 · tm233517-3_4seq1.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,953 F1 · price: The shares of Common Stock were issued to the Reporting Person pursuant to the Issuer's 2020 Equity Compensation Plan in lieu of the non-employee director board and committee cash retainers of $60,500 in the aggregate owed to the Reporting Person for service on the board of directors in 2022. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,484 | $0.00 Strike: $67.03 | $0.00 |
DisclosureSEC source: 0000899243-22-039404 · doc4.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,484 Underlying: Common Stock · 4,484 shares Expires 2032-12-22 F1 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:01 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001104659-22-073094 · tm2218674-2_4seq1.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,340 | $0.00 Strike: $79.29 | $0.00 |
DisclosureSEC source: 0000886163-22-000079 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,340 Underlying: Common Stock · 4,340 shares Expires 2032-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 22:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-22-000079 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,402 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2022. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,835 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000886163-21-000136 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,835 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,835 | $161.86 | $782,579.08 |
DisclosureSEC source: 0000886163-21-000136 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,398 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.36 to $164.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 22:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,835 | $32.30 | $156,170.50 |
DisclosureSEC source: 0000886163-21-000136 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,269 | $0.00 Strike: $115.39 | $0.00 |
DisclosureSEC source: 0000886163-21-000089 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2031-06-04 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:24 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 630 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000089 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,398 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 00:01 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-21-075261 · tm2118079d3_4seq1.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest 25% every quarter after the grant date. Read SEC document |
| May 24, 2021 Filed May 27, 2021 01:26 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 5,102 | $18.58 | $94,795.16 |
DisclosureSEC source: 0001104659-21-072617 · tm2117684-1_4seq1.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,828 Read SEC document |
| May 24, 2021 Filed May 27, 2021 01:26 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 338 | $18.44 | $6,232.72 |
DisclosureSEC source: 0001104659-21-072617 · tm2117684-1_4seq1.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,726 Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:12 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001104659-20-122029 · a4.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-11-03 F1 · security: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:11 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 11,111 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 4 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Common Stock · 11,111 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:11 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 11,111 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series A Convertible Preferred Stock · 11,111 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:11 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionSeries A Convertible Preferred Stock · Derivative | 46,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054315 · doc4.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:11 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionCommon Stock | 46,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054315 · doc4.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0000886163-20-000075 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 2,468 shares Expires 2030-06-10 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000075 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,768 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 23:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000886163-19-000138 · edgardoc.xml · derivative · entry 3 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,835 Underlying: Common Stock · 2,500 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 23:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 847 | $95.58 | $80,958.29 |
DisclosureSEC source: 0000886163-19-000138 · edgardoc.xml · nonDerivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,937 F1 · shares: Represents shares withheld by the Issuer in payment of the exercise price of options. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 23:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 2,500 | $32.30 | $80,750.00 |
DisclosureSEC source: 0000886163-19-000138 · edgardoc.xml · nonDerivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 19:33 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000899243-19-018474 · doc4.xml · derivative · entry 1 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-06-26 F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:46 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,071 | $0.00 Strike: $113.59 | $0.00 |
DisclosureSEC source: 0000886163-19-000104 · edgardoc.xml · derivative · entry 2 LAMATTINA JOHN L · CIK 0001216074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071 Underlying: Common Stock · 4,071 shares Expires 2029-06-06 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.